FDA approves Cobenfy, a new treatment for schizophrenia
HQ Team 27 September, 2024: The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in.
Drugs
Health
Pharma
Drugs
Health
Pharma
Bristol’s oral drug to treat Crohn’s disease fails remission test
HQ Team March 29, 2024: Bristol Myers Squibb’s final stage clinical trials for its Zeposia oral drug, to treat moderate to severe Crohn’s.
Drugs
Health
Pharma
Bristol Myers says liver cancer therapy trial improves overall survival rate
HQ Team March 20, 2024: Bristol Myers Squibb, a New Jersey-based drugmaker, announced it has met its primary goal of improved overall survival.
Drugs
Health
Pharma
Bristol Myers to acquire Karuna Therapeutics for $14 billion
HQ Team December 23, 2023: Bristol Myers Squibb will buy US-based biotech company, Karuna Therapeutics for $14 billion to expand its neuroscience portfolio,.
Drugs
Health
Pharma
Bristol Myer to pay China’s drugmaker Sichuan $8.4b to develop cancer drug
HQ Team December 12, 2023: Bristol Myers Squib will pay a total of $8.4 billion to SystImmune Inc., the US arm of Chinese.
Drugs
Health
Pharma
Bristol Myers acquires Mirati Therapeutics for $5.8 billion
HQ Team October 9, 2023: Bristol Myers Squibb, one of the world’s largest pharmaceutical companies, will acquire Mirati Therapeutics for $5.8 billion through.
Drugs
Health
Pharma
Merck gets priority review nod from USFDA for hypertension drug
HQ Team September 28, 2023: Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by.